Why invest in GSK?
Because we unite science, technology and talent to deliver strong and sustainable shareholder returns as a company where our people can thrive.
Our step-change in growth
- Expected sales growth of 3-5%* and core operating profit growth of 7-9%* in 20266
- Ambition to deliver >£40 billion* sales by 2031
*View our cautionary statement regarding forward-looking statements
ANNUAL REPORT 2025
We are a focused biopharma company with strong momentum and big ambitions
Business model
We improve the health of hundreds of millions of people around the world by discovering, developing and manufacturing innovative specialty medicines, vaccines and general medicines at scale.
We invest in outstanding people
Central to our success are our people. We also collaborate with world-leading experts and form strategic partnerships to complement our existing capabilities.
Our progress in 2025
By combining our understanding of the science of the immune system with cutting-edge technology, we can discover and develop new medicines and vaccines with the potential to transform people’s lives.
Assets in the pipeline
58Assets in phase III/registration
17FDA approvals in 2025
5
Business sustainability
Being a responsible business is vital to our strategy and long-term success. It helps us build and sustain trust with our stakeholders, reduce risk, support our people to thrive and deliver positive health impact at scale.
To deliver on our purpose, we must consider our impacts, risks and opportunities across everything we do, in our business and value chain. We focus on six areas to help us address what’s most material to our business and most important to our stakeholders:
Governance
We are committed to operating at the highest standards of corporate governance. We believe our governance structure underpins our ability to deliver the Group's strategy to create long-term value and benefit for our shareholders and stakeholders.
*defined on page 53 of FY 2025 press release
